Outcomes by tumor histology and kras mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer

Clinical Lung Cancer

Volumn 16, Issue 1, 2015, Pages 24-32

  Mak, Raymond H ^a,b   Hermann, Gretchen ^a   Lewis, John H ^a,b   Aerts, Hugo J W L ^a,b   Baldini, Elizabeth H ^a,b   Chen, Aileen B ^a,b   Colson, Yolonda L ^a,b   Hacker, Fred H ^a,b   Kozono, David ^a,b   Wee, Jon O ^a,b   Chen, Yu Hui ^c   Catalano, Paul J ^c,d   Wong, Kwok Kin ^b,c   Sher, David J ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Early stage; KRAS; Non small cell lung cancer; Stereotactic body radiotherapy

Indexed keywords

K RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; DISTANT METASTASIS; EARLY CANCER; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENOTYPE; HISTOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RADIATION RESPONSE; RECURRENCE FREE SURVIVAL; SMOKING; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; VERY ELDERLY; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; RADIOSURGERY; SURVIVAL;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RADIOSURGERY; RAS PROTEINS; SURVIVAL ANALYSIS;

EID: 84927554572     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2014.09.005     Document Type: Article

References (22)

1. P. Baumann, J. Nyman, and M. Hoyer Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy J Clin Oncol 27 2009 3290 3296
2. R. Timmerman, R. Paulus, and J. Galvin Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
3. A.J. Fakiris, R.C. McGarry, and C.T. Yiannoutsos Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study Int J Radiat Oncol Biol Phys 75 2009 677 682
4. H. Onishi, T. Araki, and H. Shirato Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study Cancer 101 2004 1623 1631
5. I.S. Grills, V.S. Mangona, and R. Welsh Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer J Clin Oncol 28 2011 928 935
6. S. Senthi, F.J. Lagerwaard, C.J. Haasbeek, B.J. Slotman, and S. Senan Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis Lancet Oncol 13 2012 802 809
7. L. Ding, G. Getz, and D.A. Wheeler Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
8. M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 2010 2380 2388
9. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
10. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
11. Y. Loriot, P. Mordant, E. Deutsch, K.A. Olaussen, and J.C. Soria Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6 2009 528 534
12. J.L. Marks, S. Broderick, and Q. Zhou Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
13. S. Cuffe, A. Bourredjem, and S. Graziano A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer J Thorac Oncol 7 2012 963 972
14. J.E. Chaft, V. Rusch, and M.S. Ginsberg Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers J Thorac Oncol 8 2013 1084 1090
15. F.A. Shepherd, C. Domerg, and P. Hainaut Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol 31 2013 2173 2181
16. J.H. Schiller, S. Adak, and R.H. Feins Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy J Clin Oncol 19 2001 448 457
17. R.J. Slebos, R.E. Kibbelaar, and O. Dalesio K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 1990 561 565
18. R.H. Mak, E. Doran, and A. Muzikansky Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC Oncologist 16 2011 886 895
19. R.H. Mak, E. Doran, and A. Muzikansky KRAS mutation is associated with decreased overall survival after thoracic radiation therapy in patients with locally advanced non-small cell lung cancer Int J Radiat Oncol Biol Phys 78 2010 S36
20. H.K. Ahn, Y.L. Choi, and J.H. Han Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery Lung Cancer 79 2013 300 306
21. D.A. Eberhard, B.E. Johnson, and L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
22. H. Ji, M.R. Ramsey, and D.N. Hayes LKB1 modulates lung cancer differentiation and metastasis Nature 448 2007 807 810